Global Dopamine Agonists Market Size To Worth USD 5.031 Billion By 2033 | CAGR of 6.32%
Category: HealthcareGlobal Dopamine Agonists Market Size To Worth USD 5.031 Billion By 2033
According to a research report published by Spherical Insights & Consulting, the Global Dopamine Agonists Market Size is Expected to Grow from USD 2.725 Billion in 2023 to USD 5.031 Billion by 2033, at a CAGR of 6.32% during the forecast period 2023-2033.
Get more details on this report -
Browse key industry insights spread across 250 pages with 130 Market data tables and figures & charts from the report on the " Global Dopamine Agonists Market Size, Share, and COVID-19 Impact Analysis, By Drug Type (Non-Ergot Dopamine Agonists and Ergot Dopamine Agonists), By Route of Administration (Injectables, Oral, and Others), By Indications (Hyperprolactinemia, Parkinson’s Disease, Restless Legs Syndrome (RLS), and Others), By Distribution Channel (Drug Store & Retail Pharmacies, Hospital Pharmacies, and Online Pharmacies), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2023 – 2033." Get Detailed Report Description Here: https://www.sphericalinsights.com/reports/dopamine-agonists-market
The global dopamine agonists market is a pharmaceutical sector that develops and commercializes medications that mimic dopamine's effects. These medications are used to treat movement problems, particularly Parkinson's disease, and are used as first-line treatments for neuroleptic malignant syndrome and restless legs syndrome. They have variable degrees of nonselective binding to the five different types of dopamine receptors (D1–D5). Government initiatives, such as the National Institute of Neurological Disorders and Stroke (NINDS), drive market growth. Pharmaceutical companies are investing in research to create cutting-edge formulations like transdermal and extended-release patches to improve patient compliance and market penetration. The rising prevalence of neurological conditions like Parkinson's and restless legs syndrome is fueled by government financing and reimbursement policies. However, adverse effects may impede the market growth.
The non-ergot dopamine agonists segment held the largest share in 2023 and is predicted to grow at a significant CAGR during the predicted period.
Based on the drug type, the global dopamine agonists market is categorized as non-ergot dopamine agonists and ergot dopamine agonists. Among these, the non-ergot dopamine agonists segment held the largest share in 2023 and is predicted to grow at a significant CAGR during the predicted period. This is driven by improved safety, drug delivery system innovations, research, neurodegenerative disease cases, rapid action, minimal adverse effects, and reduced motor symptoms.
The oral segment accounted for the highest market share in 2023 and is expected to grow at a CAGR of 6.28% throughout the projected timeframe.
Based on the route of administration, the global dopamine agonists market is categorized as injectables, oral, and others. Among these, the oral segment accounted for the highest market share in 2023 and is expected to grow at a CAGR of 6.28% throughout the projected timeframe. Patient compliance, safety, cost-effectiveness, non-invasiveness, convenience of administration, suitability for both pediatric and geriatric patients, and the lack of need for appropriate sterilization are all factors contributing to the sector's growth.
The Parkinson’s disease segment accounted for the highest market share of 47.11% in 2023 and is expected to grow at a significant CAGR throughout the projected timeframe.
Based on the indications, the global dopamine agonists market is categorized as hyperprolactinemia, Parkinson’s disease, restless legs syndrome (RLS), and others. Among these, the Parkinson’s disease segment accounted for the highest market share of 47.11% in 2023 and is expected to grow at a significant CAGR throughout the projected timeframe. The rising incidence of Parkinson's disease, dopamine depletion, heredity, and environmental factors are all attributed to the segment's expansion.
The hospital pharmacies segment accounted for a substantial share in 2023 and is expected to grow at a significant CAGR throughout the projected timeframe.
Based on the distribution channel, the global dopamine agonists market is categorized as drug store & retail pharmacies, hospital pharmacies, and online pharmacies. Among these, the hospital pharmacies segment accounted for a substantial share in 2023 and is expected to grow at a significant CAGR throughout the projected timeframe. This is attributed to increased hospital admissions, improvements in hospitals and pharmacies, wide availability of dopamine agonist injectables, immediate access to medications, counseling, and dispensing facilities.
North America is expected to hold the greatest share of the global dopamine agonists market over the forecast period.
Get more details on this report -
North America is expected to hold the greatest share of the global dopamine agonists market over the forecast period. The North American dopamine agonists market is fueled by neurological disorders, drug formulation advancements, increased awareness, and next-generation therapies. The US healthcare infrastructure, public health campaigns, and continuous drug development investments contribute to faster diagnosis and treatment access, resulting in increased patient treatment.
Asia Pacific is predicted to grow at the fastest CAGR throughout the estimated period. The Asia Pacific dopamine agonists market is driven by factors such as neurological conditions, improved healthcare facilities, increased awareness, new dopamine agonists, and economic expansion. Research and development efforts, along with the pharmaceutical industry expansion, have produced improved safety and efficacy profiles. Government programs and policies, particularly in China, have also contributed to market growth.
Major key players in the global dopamine agonists market are Boehringer Ingelheim Pharmaceuticals, Kirin Holdings Company, Teva Pharmaceutical Industries, Adamas Pharma, GlaxoSmithKline (GSK), Novartis, Avvisto Therapeutics (VeroScience), UCB Pharma, Amneal Pharmaceuticals, Pfizer, Sunovion Pharmaceuticals, AbbVie, and others.
Key Target Audience
- Market Players
- Investors
- End-users
- Government Authorities
- Consulting and Research Firm
- Venture capitalists
- Value-Added Resellers (VARs)
Recent Development
- In February 2025, Supernus Pharmaceuticals received FDA approval for ONAPGO, a subcutaneous apomorphine infusion device, to treat motor fluctuations in adults with advanced Parkinson's disease. The FDA approved ONAPGO, formerly known as SPN-830, and available in the second quarter of 2025. Supernus provides expert support, including a nurse education program, and access support at launch.
Market Segment
This study forecasts revenue at the global, regional, and country levels from 2023 to 2033. Spherical Insights has segmented the global dopamine agonists market based on the below-mentioned segments:
Global Dopamine Agonists Market, By Drug Type
- Non-Ergot Dopamine Agonists
- Ergot Dopamine Agonists
Global Dopamine Agonists Market, By Route of Administration
- Injectables
- Oral
- Others
Global Dopamine Agonists Market, By Indications
- Hyperprolactinemia
- Parkinson’s Disease
- Restless Legs Syndrome (RLS)
- Others
Global Dopamine Agonists Market, By Distribution Channel
- Drug Store & Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies
Global Dopamine Agonists Market, By Region
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia Pacific
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- UAE
- Saudi Arabia
- Qatar
- South Africa
- Rest of the Middle East & Africa
About the Spherical Insights & Consulting
Spherical Insights & Consulting is a market research and consulting firm which provides actionable market research study, quantitative forecasting and trends analysis provides forward-looking insight especially designed for decision makers and aids ROI.
Which is catering to different industry such as financial sectors, industrial sectors, government organizations, universities, non-profits and corporations. The company's mission is to work with businesses to achieve business objectives and maintain strategic improvements.
CONTACT US:
For More Information on Your Target Market, Please Contact Us Below:
Phone: +1 303 800 4326 (the U.S.)
Phone: +91 90289 24100 (APAC)
Email: inquiry@sphericalinsights.com, sales@sphericalinsights.com
Contact Us: https://www.sphericalinsights.com/contact-us
Need help to buy this report?